Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171184 · ClinicalTrials.gov registry record · Phase 4
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
A Phase 4 study of Overactive Bladder, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT00171184: Completed Phase 4 study of Overactive Bladder, sponsored by Novartis.
NCT00171184 is a Phase 4 study of Overactive Bladder that has completed, run by Novartis. The registered enrollment target is 400 participants, above the 199-participant average among 46 other Overactive Bladder trials with a reported enrollment target (101% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00171184, a Phase 4 study of Overactive Bladder, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to assess the efficacy, safety and tolerability of 12-weeks treatment with darifenacin in patients aged \>Ý 65 years with OAB.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Darifenacin
Study Locations (1)
Texas
- Scott Department of Urology Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-06 |
| Phase | Phase 4 |
What the finished NCT00171184 record still lists
NCT00171184 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 199-participant average among 46 other Overactive Bladder trials with a reported enrollment target (101% higher).
The record links to 1 condition, with Overactive Bladder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00171184 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00171184 about?
NCT00171184 is a clinical study titled "Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder". The objective of this study is to assess the efficacy, safety and tolerability of 12-weeks treatment with darifenacin in patients aged \>Ý 65 years with OAB.
What is the current status of trial NCT00171184?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2005-04. Estimated completion is 2006-06.
What conditions does trial NCT00171184 study?
This clinical trial studies the following conditions: Overactive Bladder.
What interventions are being tested in trial NCT00171184?
The interventions under investigation include: Placebo (DRUG), Darifenacin (DRUG).
Who is sponsoring clinical trial NCT00171184?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00171184 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00171184's enrollment target sits among peer trials
400 5th of 46 higher than 42 of 46 other Overactive Bladder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overactive Bladder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bladder Botox UTI Antibiotic Prophylaxis
RECRUITING · Phase 4
-
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
RECRUITING · Phase 4
-
Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks
RECRUITING · Phase 4
-
TReating Incontinence for Underlying Mental and Physical Health
RECRUITING · Phase 4
-
Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
COMPLETED · Phase 4
-
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia